Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Irland - Englisch - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - triptorelin - powder and solvent for prolonged-release suspension for injection - 22.5 milligram(s) - triptorelin

Irland - Englisch - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - triptorelin - powder and solvent for prolonged-release suspension for injection - 22.5 milligram(s) - triptorelin

Irland - Englisch - HPRA (Health Products Regulatory Authority)

originalis b.v. - triptorelin - powder and solvent for suspension for injection - 11.25 milligram(s) - triptorelin

Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - triptorelin acetate - misc. intra vaginal/uterine prep/device - triptorelin acetate anthelmintic active 100.0 ug/ml - endocrine system

Neuseeland - Englisch - Ministry for Primary Industries

vetoquinol new zealand limited - triptorelin acetate - triptorelin acetate 0.01 g/litre - endocrine agent (hormone)

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - triptoreline pamoate -

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - triptorelin - powder and solvent for suspension for injection - 11.25mg

Israel - Englisch - Ministry of Health

medison pharma ltd - triptorelin as acetate - powder and solvent for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - prostate cancer: treatment of prostate cancer with metastases. patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. precocious puberty: (before 8 years in girls and 10 years in boys). genital and extragenital endometriosis (stage i to stage iv): treatment should not be administered for more than 6 months. it is not recomended to start a second treatment course with triptorelin or another gnrh analogue. treatment of uterine fibromyomas prior to surgery: associated with anaemia ( haemoglobin less than, or equal to 8 g/dl). when a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. the treatment duration is restricted to 3 months. female infertility: supplementary treatment in combination with gonadotrophins (hmg, fsh, hcg) to induce ovulation with a view to in vitro fertilisa

Israel - Englisch - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - powder and solvent for suspension for injection - triptorelin as embonate 3.75 mg ml - triptorelin - triptorelin - - lowering of sexual hormones and - treatment of advanced hormone-dependent prostate cancer. - central precocious puberty.- as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor of hormone receptor-positive early stage breast cancer in women at high risk of recurrence and who are confirmed as pre-menopausal after completion of chemotherapy and in men at high risk of recurrence